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A pilot study of pancreatic islet amyloid PET imaging
with [18F]FDDNP
Zhi Lua,*, Jinghui Xiea,*, Ran Yanc,*, Zilin Yuc, Zhigang Sunb, Fei Yua,
Xiaoyan Gonga, Hongbo Fenga, Jing Lua and Yanjun Zhanga
Objectives Pancreatic islet amyloid deposition occurs
before β-cell damage in type 2 diabetes mellitus patients.
The islet and Alzheimer’s disease β-amyloid shares similar
secondary structures. The Alzheimer’s disease β-amyloid
targeting tracer [18F]FDDNP could be used to image
pancreatic islet amyloid with PET.
Patients and methods Consecutive pancreatic tissue
sections from a 69-year-old male type 2 diabetes mellitus
patient were stained by hematoxylin and eosin, anti-amylin
antibody, Congo Red, periodic acid-Schiff, and [18F]FDDNP
reference compound, respectively. The pancreatic tissue
sections were also incubated with [18F]FDDNP with and
without its reference compound for autoradiography.
Subsequently, we performed control [18F]FDDNP pancreatic
PET/CT imaging in four healthy individuals. The mean
standardized uptake values of [18F]FDDNP uptake in the
pancreatic head, neck, body, and tail, blood pool, liver, and
vertebral bone from 5 to 120min after injection were
determined.
Results Islet amyloid was observed in all four standard
staining methods in the pancreas tissue. Similar islet
amyloid distribution and phenotypes were observed clearly
in the [18F]FDDNP reference compound-stained pancreas
tissue. [18F]FDDNP was intensively accumulated in the
same pancreatic tissue in autoradiography, which was
largely blocked by its reference compound. In the PET/CT
scans of control human participants, the mean standardized
uptake values in pancreas decreased to the blood pool level
in 30min and all parts of the pancreas had similar [18F]
FDDNP uptake. The pancreas could be distinguished clearly
from the liver at all-time points.
Conclusion These results suggested that [18F]FDDNP is a
potential tracer for pancreatic islet amyloid PET
imaging. Nucl Med Commun 00:000–000 Copyright © 2018
The Author(s). Published by Wolters Kluwer Health, Inc.
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Introduction
Diabetes is a chronic progressive disease characterized by
elevated levels of blood glucose. The prevalence of
diabetes has been increasing steadily for the past three
decades and is growing most rapidly in low-income and
middle-income countries. Diabetes caused 1.5 million
deaths in 2012. In 2014, 422 million individuals in the
world had diabetes, a prevalence of 8.5% among the adult
population [1].
Type 2 diabetes mellitus (T2DM) accounts for the vast
majority of diabetes patients, and is characterized by islet
β-cell damage and dysfunction. Amyloid deposits can be
found in the pancreatic islets around β cells in over 90%
of T2DM patients [2,3]. Human islet amyloid polypep-
tide is a 37-residue amyloidogenic peptide hormone
secreted primarily by pancreatic β cells in the islet of
Langerhans simultaneously with insulin [4]. In-vitro
studies have suggested that the human islet amyloid
polypeptide has a concentration-dependent amyloido-
genic propensity that causes cell membrane disruption,
channel formation, and cytotoxicity. The resulting inso-
luble plaques have the characteristic β-sheet structure of
amyloidogenic proteins [5]. Furthermore, islet amyloi-
dosis occurs uniformly throughout the pancreas, affecting
all islets before severely damaging their functions.
Reduction of islet endocrine mass also occurs at this early
stage of islet amyloid development and progresses as the
amyloid mass increases [6]. In a study on monkeys, glu-
cose tolerance deteriorated as the amount of islet amyloid
increased [7]. In addition, islet amyloidosis appears to be
associated with a reduction in islet β-cell mass, especially
The data were presented previously at the SNMMI 2015 Annual Meeting and
published as an abstract in J Nucl Med 2015; 56:1067.
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when marked islet amyloid is present [8,9]. These
researches indicate that amyloid deposition occurs before
β-cell damage in pancreatic islets and consequently the
symptom of high blood glucose levels appears.
Currently, the only clinical method to diagnose pancreatic
islet amyloid is through invasive autopsy. Thus, there is an
unmet need to develop a noninvasive imaging method to
quantitatively measure the pancreatic islet amyloid burden
in T2DM patients. So far, only one molecular probe,
99mTc-labeled pyridyl benzofuran, has been evaluated
in vivo on the islet amyloid mouse model with single-
photon emission computed tomography [10]. It showed a
1.6-fold higher uptake in the pancreas of the model mice
than the control mice at 1 h after injection. Recently, [18F]
FDDNP has shown great promise in the detection of
β-amyloid burden in Alzheimer’s diseases (AD) patients
[11,12]. As the islet and AD β-amyloid has a similar sec-
ondary structure [13], we envisage that [18F]FDDNP could
be applied for the detection of islet amyloid with PET.
In this study, we showed that [18F]FDDNP selectively
stained the human pancreas islet amyloid. This specific
binding was proved by autoradiography. We also evaluated
the distribution and the clearance of [18F]FDDNP in
healthy humans to confirm that it has favorable pharma-
cokinetics as a potential islet amyloid PET tracer.
Patients and methods
The ethical consideration
The use of patients’ tissue and imaging data in this study
was approved by the Institute Research Medical Ethics
Committee of First Affiliated Hospital of Dalian Medical
University. Informed written consent was obtained from
all patients before the study.
General information
Paraffin-embedded human pancreas samples from a
T2DM patient (a 69-year-old man) and a healthy indivi-
dual (a 72-year-old woman) were generously provided by
the Department of Pathology, the First Affiliated Hospital
of Dalian Medical University, People’s Republic of China.
The pancreas samples were cut into 3–5mm thick sections
that were either used immediately after deparaffinization
or after the antigen retrieval procedure involving 30min of
autoclaving at 121°C in distilled water and subsequent
incubation in 96% formic acid for 5min, which is the
standard pretreatment for pancreas islet amyloid immu-
nostain detection [14]. The presence of islet amyloid was
determined by two senior pathologists independently.
Hematoxylin and eosin staining
The dewaxed and hydrated human pancreas tissue sec-
tions were incubated with alum haematoxylin solution at
room temperature (RT) for 5 min before rinsing with
distilled water for 1 min, 1% HCl in ethanol for 20 s, and
distilled water for 1 min. The sections were then incu-
bated with 0.5% eosin at RT for 2 min, rinsed with
distilled water for 1 min, dehydrated, and mounted with
glycerol before observation under a Nikon Eclipse E600
microscope with a Nikon DXM 1200 digital camera
(Nikon, Tokyo, Japan) (×200 objective).
Congo Red staining
The dewaxed and hydrated human pancreas tissue sec-
tions were incubated with alum haematoxylin solution at
RT for 2min and then in 0.5% HCl in ethanol for 20 s
before rinsing with distilled water twice for 5min. The
sections were then incubated in 1% Congo Red solution at
RT for 25min, rinsed with distilled water for 2min,
dehydrated, and mounted with glycerol before observation
under a Nikon Eclipse E600 microscope with a Nikon
DXM 1200 digital camera (Nikon) (×200 objective).
Periodic acid-Schiff staining
The dewaxed and hydrated human pancreas tissue sec-
tions were incubated in 0.5% periodic acid water solution
at RT for 20 min before rinsing with distilled water twice.
The sections were then incubated with Schiff reagent at
RT for 10 min until the sections became light pink in
color and were then washed with distilled water till the
sections turned into a dark pink color in 5 min.
Subsequently, the sections were incubated with hema-
toxylin for 2 min and then in 0.5% HCl in ethanol for 10 s
before washing with distilled water, dehydrated, and
mounted with glycerol before observation under a Nikon
Eclipse E600 microscope with a Nikon DXM 1200 digital
camera (Nikon) (×200 objective).
Immunohistochemistry
The dewaxed and hydrated human pancreas tissue sec-
tions were washed with PBS three times, incubated with
normal horse serum 4% in PBS at RT for 20min, and then
the anti-amylin antibody (10 μg/ml, ab11022; Abcam,
Bristol, UK) at 4°C for 18 h. Subsequently, the sections
were incubated with maxvision/HRP for 15min, washed
with PBS three times, and rinsed with 3,3′-diaminobenzi-
dine till the color developed. The sections were washed
with distilled water and then incubated with hematoxylin
for 2min before washing with distilled water, dehydrated,
and mounted with glycerol before observation under a
Nikon Eclipse E600 microscope with a Nikon DXM 1200
digital camera (Nikon) (×200 objective).
[18F]FDDNP fluorescence staining
The dewaxed and hydrated human pancreas tissue sec-
tions were incubated with 1% Sudan black in a 70%
ethanol solution at RT for 5 min and rinsed with distilled
water and 70% ethanol. The sections were then incu-
bated in [18F]FDDNP (5 μmol/l; ABX company,
Radeberg, Germany) in the dark for 30 min, rinsed with
distilled water for 2 min, and mounted with glycerol
before observation under an EVOS FL Imaging System
(Thermo Fisher; Waltham, Massachusetts, USA) (×200
objective) with GFP Light Cube [15].
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[18F]FDDNP autoradiography and blocking with its
reference compound
The [18F]FDDNP was prepared on the basis of a pre-
viously published method [16]. The dewaxed and hydra-
ted human pancreas tissue sections were incubated in [18F]
FDDNP PBS solution (0.13MBq/ml) with or without its
nonradioactive reference compound (0.44mg/ml) in the
dark for 20min. The sections were then washed with
distilled water and air dried before exposure to a multi-
sensitive phosphor screen (PerkinElmer; Waltham,
Massachusetts, USA) at RT for 5min. The phosphor
screen was then scanned in a Typhoon 8600 phosphor
imager (GE Healthcare; Pittsburgh, Pennsylvania, USA) at
a resolution of 50 µm. The images were analyzed using
OptiQuant (version 5.0; PerkinElmer) software.
[18F]FDDNP dynamic pancreas PET/CT imaging
Four healthy volunteers (Table 1) received [18F]FDDNP
(370MBq) and subjected to a pancreatic three-dimensional
mode dynamic PET/CT scan (Biograph 64; Siemens AG,
Muenchen, Germany) from 5 to 120min after intravenous
injection, respectively. The pancreas was localized by a
care-dose (quality reference current 170mAs, 120 kVp, free
tidal breathing) computed tomography (CT) scan. The
images were reconstructed using True X with a 168× 168
matrix size, ordered-subsets expectation maximization
(three iterations, 21 subsets, zoom 1), and postfilter full-
width at half-maximum of 4mm. Quantitative image ana-
lysis was based on the transaxial frames of [18F]FDDNP
DICOM series images by drawing the Region of Interest
(ROI) with a diameter of 0.8 cm and then measuring the
mean standardized uptake values (SUVmean) of radio-
activity uptake in the whole pancreas including head, neck,
body and tail, blood pool (abdominal aorta at the lumbar
level L1, L2), liver (right lobe), and vertebral bone. On the
DICOM reconstructed images, a ROI standard-sized
region with a diameter of 0.8 cm in the center of the
abdominal aorta at the lumbar level (L1, L2) was used to
measure the blood pool SUVs; and in the whole pancreatic,
the right lobe of liver, and vertebral bone in sight.
Results
Islet amyloids detected in the human pancreas tissue by
H&E staining
To confirm the presence of islet amyloids in the human
pancreas tissue from a T2DM patient (a 69-year-old man),
we stained its section slides with H&E. A large number of
islet amyloids were observed as light red clusters in the
pancreatic islet indicated by the arrows (Fig. 1a).
Islet amyloids’ detection by the [18F]FDDNP reference
compound
To demonstrate the ability of [18F]FDDNP to detect
islet amyloids, we stained the consecutive pancreas tissue
sections from a T2DM patient (a 69-year-old man) using
the standard islet amyloid detecting methods, such as the
Congo Red, periodic acid-Schiff (PAS), and anti-amylin
antibody, to compare with that of the [18F]FDDNP
reference compound. The islet amyloids in the pancreas
tissue sections were visualized by the Congo Red as
orange red clusters, the PAS as pink clusters, and the
anti-amylin antibody as brown clusters indicated by the
arrows under bright-field microscopy (Fig. 1b–d). The
islet amyloids were also detected by the [18F]FDDNP
reference compound as bright yellow clusters with
fluorescence imaging (Fig. 1e). In contrast, when healthy
human pancreas tissue sections (a 72-year-old woman)
were incubated with the [18F]FDDNP reference com-
pound, little [18F]FDDNP residual was retained in the
tissue after washing with water (Fig. 1f).
[18F]FDDNP binding to islet amyloids in human pancreas
tissue sections
The [18F]FDDNP was prepared using an Explora GN
modular lab (Siemens AG; Muenchen, Germany) in
nondecay correct isolated radiochemical yields of
10.4 ± 1.8% (n= 5) with a radiochemical purity of more
than 99% with a specific activity of 86 GBq/μmol using an
established literature method [16]. We investigated the
selectivity and specificity of [18F]FDDNP to bind to islet
amyloids in human pancreas tissue sections using an
autoradiograph. The dewaxed and hydrated human
pancreas tissue sections from a T2DM patient (a 69-year-
old man) were incubated in an [18F]FDDNP PBS solu-
tion with or without its reference compound in the dark
before exposure to a multisensitive phosphor screen. The
phosphor screen was then scanned in a Typhoon 8600
phosphor imager. The autoradiograph images showed
that [18F]FDDNP accumulated in the islet amyloids as
dots and patches in the human pancreas tissue sections
(Fig. 2a and c). The specific uptake of these islet amyloids
was largely blocked by the FDDNP reference compound
in the continuous tissue section (Fig. 2b and c).
[18F]FDDNP rapidly cleared from pancreas in controls
without T2DM
Four individuals without T2DM who had received [18F]
FDDNP were subjected to pancreatic three-dimensional
mode dynamic PET/CT scans from 5 to 120 min after an
intravenous injection, respectively. The pancreas was
localized by a care-dose CT scan. To quantify the
radioactivity uptake in the entire pancreas including the
head, neck, body, and tail, blood pool, liver, and vertebral
Table 1 Characteristics of human participants in the PET study
Patients
Age
(years) Sex
Pancreas
disease T2DM
Fasting blood
glucose level
(mmol/l)
1 29 Female No No 5.0
2 53 Female No No 6.0
3 63 Female No No 4.6
4 60 Male No No 5.7
T2DM, type 2 diabetes mellitus.
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bone, the SUVmean were determined by drawing the ROI
on the transaxial frames of [18F]FDDNP series images.
The mean SUVs of the pancreas were decreased to close
to the blood pool level 30 min post intravenous injection
(Fig. 3a). Furthermore, the pancreatic head, neck, body,
and tail had similar [18F]FDDNP uptake throughout the
PET scan, showing an initial increased uptake in the first
5 min, gradually decreasing till 60 min, and reaching a
plateau from 60 to 120 min (Fig. 3b). Moreover, in the
transaxial PET images of [18F]FDDNP PET/CT scan of
the control human participant (Fig. 4), the pancreas could
be clearly visualized and distinguished from the liver and
other metabolism organs at all-time points from 5 to
120 min despite the fact that the SUVmean from the liver
and bone were slightly higher than those in the pancreas.
Gradual radioactivity accumulation and excretion in the
gallbladder, the bright spot close to the pancreatic head,
was also observed from the PET images in Fig. 4.
Discussion
There are strong evidences that T2DM and AD are closely
associated protein misfolding disorders and the islet and
AD β-amyloid shares similar secondary structures [11,12].
Thus, an AD PET tracer such as [18F]FDDNP could be
Fig. 1
100∝m 100∝m 100∝m
100∝m 100∝m 100∝m
(d) (e) (f)
(a) (b) (c)
(a) H&E staining of a T2DM patient’s pancreas tissue section; (b–d) continuous pancreas tissue sections staining from the same T2DM patients’
pancreas tissue: (b) Congo Red; (c) PAS; (d) anti-amylin antibody IHC staining; (e) fluorescence from FDDNP; (f) FDDNP staining with a human
pancreas tissue section without T2DM. The white arrows in (a-e) indicate the locations of the amyloid in the pancreas tissue sections.
Fig. 2
(a–d) Autoradiography of a type 2 diabetes mellitus patient’s pancreas
tissue sections. (a, c) incubated with [18F]FDDNP alone; (b, d)
incubated with [18F]FDDNP in the presence of its nonradioactive
reference compound.
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used for the noninvasive imaging of islet amyloid in T2DM
patients. We investigated its suitability to detect islet
amyloids in humans with the added advantage that it could
measure the amyloid burden in both the central nervous
system and the peripheral organs at the same time, which
might unveil the interrelationship of these two age-related
diseases at the molecular level.
Initially, we confirmed the presence of islet amyloids
in the human pancreas tissue from a T2DM patient
(a 69-year-old man) using the H&E histology method.
The islet amyloids were observed as light red clusters
and distributed heterogeneously in this pancreas speci-
men. In the subsequent comparison staining study, we
observed the islet amyloids as bright yellow clusters
stained by the [18F]FDDNP reference compound with
fluorescence imaging. These islet amyloids have dis-
tributions and phenotypes similar to those in the con-
tinues human pancreas tissue sections detected by the
standard islet amyloid staining methods using Congo
Red, PAS, and anti-amylin antibody. In the control
experiment, [18F]FDDNP was not retained in the heal-
thy human pancreas tissue. These data gave us the
confidence that FDDNP can be used to detect islet
amyloids. To further confirm that the binding between
[18F]FDDNP and the islet amyloids is selective and
specific at the tracer level, we incubated the islet amyloid
containing human pancreas tissue sections in the [18F]
FDDNP PBS solution with and without the addition of
its cold reference compound. Selective accumulation of
[18F]FDDNP in the islet amyloid-enriched regions was
observed in the autoradiography. The specific binding of
[18F]FDDNP to the islet amyloid was confirmed by the
fact that most of the [18F]FDDNP accumulation was
blocked by its reference compound.
As a small lipophilic molecule, [18F]FDDNP would show
high uptake in the liver, which could make it difficult to
visualize islet amyloid deposits in the pancreas. Thus,
before testing [18F]FDDNP on the T2DM patients, we
Fig. 3
(a) The mean standardized uptake value (SUVmean) of radioactivity retention in the pancreas, blood pool, liver, and bone in the controls. (b) The
SUVmean of radioactivity retention in the pancreatic head, neck, body, and tail, respectively, in the controls.
Fig. 4
The representative transaxial frames of the [18F]FDDNP PET/CT scan of the pancreas and the neighboring organs in a control human participant at
different time points from 5 to 120min after an intravenous injection.
PET imaging of islet amyloid with [18F]FDDNP Lu et al. 5
investigated its distribution and clearance in healthy
human volunteers. The distribution of radioactivity in
the pancreas from 5 to 120 min after an intravenous
injection was very low and could be distinguished easily
from other neighboring organs including the liver, bone,
kidney, and stomach. The SUVmean in the pancreas
became very close to the blood pool level after 30 min. In
addition, the different parts of the pancreas such as the
head, neck, body, and tail had similar low [18F]FDDNP
uptake during the PET scan. All these characteristics
generate a low background, which is essential to visualize
islet amyloids in the entire pancreas in the T2DM
patients. We believe that targeting the islet amyloidosis
for the assessment of pancreatic β-cell function in T2DM
patients rather than the direct quantification of pancreatic
β-cell mass provides an attractive alternative strategy as
the latter approach has been proven to be very challen-
ging [17]. Thus, [18F]FDDNP shows suitable in-vitro
selectivity and specificity, and in-vivo pharmacokinetics
was found to be a promising islet amyloids PET tracer.
Conclusion
We have systematically investigated the suitability of
[18F]FDDNP as a PET tracer to detect pancreatic islet
amyloid. Both the [18F]FDDNP reference compound
and the [18F]FDDNP can selectively and specifically
target the islet amyloid in human pancreas tissue. [18F]
FDDNP has low uptake and cleared rapidly from the
pancreas, blood pool, and liver in the healthy human
participants, which generated a low background to image
the islet amyloid. A clinical trial that aims to measure the
pancreatic islet amyloid burden in T2DM patients using
[18F]FDDNP is currently ongoing.
Acknowledgements
The authors would like to thank the Scientific Research
Project for Institutes of Higher Education, Ministry of
Education, Liaoning Province (L2015149), China, for
supporting this work. The research undertaken at King’s
College London was funded by the National Institute for
Health Research (NIHR) Biomedical Research Centre
based at Guy’s and St Thomas’ NHS Foundation Trust
and King’s College London, the Wellcome/EPSRC
Centre for Medical Engineering at King’s College
London (WT 203148/Z/16/Z), the King’s College
London, and the UCL Comprehensive Cancer Imaging
Centre funded by CRUK and EPSRC in association with
the MRC and DoH (UK).
Conflicts of interest
There are no conflicts of interest.
References
1 WHO. Global report on diabetes, World Health Organization; 2016 WHO/
NMH/NVI/16.3. Available at: http://www.who.int/diabetes/global-report.
[Accessed 8 August 2017].
2 Johnson KH, O’Brien TD, Betsholtz C, Westermark P. Islet amyloid, islet-
amyloid polypeptide, and diabetes mellitus. N Engl J Med 1989;
24:513–518.
3 Röcken C, Linke RP, Saeger W. Immunohistology of islet amyloid
polypeptide in diabetes mellitus: semi-quantitative studies in a post-
mortem series. Virchows Arch A Pathol Anat Histopathol 1992;
421:339–344.
4 Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and
characterization of a peptide from amyloid-rich pancreases of type 2 diabetic
patients. Proc Natl Acad Sci 1987; 84:8628–8632.
5 Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid: a long-recognized
but underappreciated pathological feature of type 2 diabetes. Diabetes
1999; 48:241–253.
6 Wang F, Hull RL, Vidal J, Cnop M, Kahn SE. Islet amyloid develops diffusely
throughout the pancreas before becoming severe and replacing
endocrine cells. Diabetes 2001; 50:2514–2520.
7 Howard CF Jr. Longitudinal studies on the development of diabetes in
individual Macaca nigra. Diabetologia 1986; 29:301–306.
8 Howard CF Jr, Van Bueren A. Changes in islet cell composition during
development of diabetes in Macaca nigra. Diabetes 1986; 35:165–171.
9 De Koning EJ, Bodkin NL, Hansen BC, Clark A. Diabetes mellitus in Macaca
mulatta monkeys is characterised by islet amyloidosis and reduction in beta-
cell population. Diabetologia 1993; 36:378–384.
10 Yoshimura M, Ono M, Watanabe H, Kimura H, Saji H. Development of (99m)
Tc-labeled pyridyl benzofuran derivatives to detect pancreatic amylin in islet
amyloid model mice. Bioconjug Chem 2016; 15:1532–1539.
11 Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al.
Binding characteristics of radiofluorinated 6-dialkylamino-
2-naphthylethylidene derivatives as positron emission tomography imaging
probes for beta-amyloid plaques in Alzheimer’s disease. J Neurosci 2001;
21:RC189.
12 Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P,
et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the
brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry
2002; 10:24–35.
13 Blázquez E, Velázquez E, Hurtado-Carneiro V, Ruiz-Albusac JM. Insulin in the
brain: its pathophysiological implications for States related with central
insulin resistance, type 2 diabetes and Alzheimer’s disease. Front Endocrinol
(Lausanne) 2014; 5:1–21.
14 Schnell SA, Staines WA, Wessendorf MW. Reduction of lipofuscin-like
autofluorescence in fluorescently labeled tissue. J Histochem Cytochem
1999; 47:719–730.
15 Bresjanac M, Smid LM, Vovko TD, Petric A, Barrio JR, Popovic M.
Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl]
ethylidene) malononitrile labels prion plaques in vitro. J Neurosci 2003;
23:8029–8033.
16 Liu J, Kepe V, Zabjek A, Petric A, Padgett HC, Satyamurthy N, Barrio JR.
High-yield, automated radiosynthesis of 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)
amino]-2-naphthyl}ethylidene) malononitrile ([18F]FDDNP) ready for animal
or human administration. Mol Imaging Biol 2007; 9:6–16.
17 Wängler B, Schneider S, Thews O, Schirrmacher E, Comagic S, Feilen P,
et al. Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-
(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([18F]
repaglinide): a promising radioligand for quantification of pancreatic beta-cell
mass with positron emission tomography (PET). Nucl Med Biol 2004;
31:639–647.
6 Nuclear Medicine Communications 2018, Vol 00 No 00
